Eupraxia Pharmaceuticals (EPRX) Analyst Day 2026 summary

Part one efficacy and endpoints

• Part one Cohorts 8b/9 showed SDI clinical remission in 71% at Week 12 and 67% at Week 52 after one treatment; Week 52 data were from 3 patients.

• EoEHSS grade and stage improved by more than 60% from baseline at Week 4 and remained more than 60% below baseline at Week 36 (n=7); reductions exceeded 50% early and remained in the 60s at month nine.

• EoEHSS improvements were similar across inflammatory and fibrotic subscores; response correlated with symptom improvement, unlike eosinophil-count reductions.

• Among patients with baseline EREFS >2, 80% reached a score ≤2 at Week 12 and 60% by Week 36; mean score reduction was 83% at Week 12 and remained 51% below baseline at Week 36.

• Part one’s open-label signals covered swallowing symptoms, tissue response and durability; Part two will add biopsies at months 3, 6, 9 and 12 to assess one-year durability.

RESOLVE Part two design and interim data

• RESOLVE Part 2 randomized 122 patients 1:1:1 to 20 injections of 6 mg or 8 mg (120 mg or 160 mg total) or vehicle; vehicle patients cross over to active treatment after Week 24 while remaining blinded.

• Protocol amendments extend follow-up from 52 weeks to two years, with biopsies and symptom assessments every three months to evaluate durability and redosing for the intended once-yearly regimen.

• The early December 2026 interim is expected to include the first 60 patients reaching Week 24 and the first 20 reaching Week 52; controlled comparison is through Week 24.

• Analyses will cover SDI, DSQ, EoEHSS, PEC, EREFS and safety; the interim is not powered for statistical significance and may include additional timepoints and endpoint analyses.

• Confidence measures include SDI remission at Weeks 24 and 52, DSQ separation from placebo at Week 24, broad EoEHSS response with EREFS context, and benefit through Week 52.

Patient population and safety

• Part 2 enrolled 122 patients; 84% had prior PPI use, 56% had failed swallowed topical corticosteroids and 18% had failed a biologic, with a 90-day washout for prior therapies.

• Part 2 baseline SDI was 5.8±1.5 versus 6.14±1.1 in Part one Cohorts 8b/9; EoEHSS grade/stage baselines were 0.33/0.34 versus 0.62/0.66, affecting absolute changes by starting severity.

• Part 2 baseline DSQ was 39.5, within the range of other trials and toward its upper end; baseline severity varied broadly, including milder patients of interest for earlier intervention.

• Across Part one and Part 2, 73% had a TEAE and 3.9% had an SAE; one patient had oropharyngeal candidiasis, with no adrenal suppression or glucose derangement reported. Data cutoff: Oct. 30, 2026.

• More than 3,000 injections were administered with no reported tissue perforations, abscesses or hematomas; the injection procedure was described as well tolerated.